Therefore, anti-APRIL treatment presents a promising alternative therapy for SLE, specifically targeting PCs with potentially fewer adverse effects compared to traditional anti-inflammatory and immunosuppressant treatments (143). Here, TNFSF13 is linked to systemic lupus erythematosus.